Los puntos clave no están disponibles para este artículo en este momento.
Despite the apparent insights into stroke pathophysiology, an abundance of promising targets in preclinical development, several underpowered phase I/II clinical trials that have detected signals of effectiveness, 151617 and all large phase II/ III randomized controlled clinical trials of neuroprotectants
Dirnagl et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: